SAHA (suberoylanilide hydroxamic acid) is a potent, reversible pan-histone deacetylase (HDAC) inhibitor. It inhibits both class I and class II HDACs. Experiments suggest that SAHA causes morphological changes, such as enlargement and flattening of the cytoplasm, resulting in growth inhibition. SAHA alters gene transcription and induces cell cycle arrest and/or apoptosis in a wide variety of transformed cells. It suppresses cell growth in a range of cancer cell lines, induces apoptosis in cutaneous T-cell lymphoma cells in-vitro. This small molecule improves reprogramming efficiency after transduction of iPSC transcription factors in mouse embryonic fibroblasts.
Peptides & proteins
MK-0683, Vorinostat, Suberoylanilide Hydroxamic Acid,Suberanilohydroxamic Acid, Zolinza, N-HydroxyN'-phenyloctanediamide
1) Butler, LM., et al. 2000. Cancer Res. 60(18): 5165-5170. PMID: 11016644; 2) Huangfu, D., et al. 2008. Nat Biotechnol. 26(7): 795-797. PMID: 18568017; 3) Zhang, Y., et al. 2012. J Cell Sci. 125(Pt 23): 5609-5620. PMID: 23420199; 4) Ma, T., et al. 2013. Circ Res. 112(3): 562-574. PMID: 23371904
-20°C. Keep away from direct sunlight.
12 months from receipt